Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.28
- Piotroski Score 3.00
- Grade Sector Outperform
- Symbol (MYGN)
- Company Myriad Genetics, Inc.
- Price $26.41
- Changes Percentage (-0.09%)
- Change -$0.03
- Day Low $26.31
- Day High $27.03
- Year High $29.30
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 07/01/2009
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 11/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $29.00
- High Stock Price Target $35.00
- Low Stock Price Target $22.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.80
- Trailing P/E Ratio -7.91
- Forward P/E Ratio -7.91
- P/E Growth -7.91
- Net Income $-112,000,000
Income Statement
Quarterly
Annual
Latest News of MYGN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Insider Sale: Chief Scientific Officer Dale Muzzey Sells Shares of Myriad Genetics Inc (MYGN)
Myriad Genetics Inc focuses on molecular diagnostic testing for disease risk assessment and treatment guidance. Insider transactions reveal selling trend, with recent sale by Dale Muzzey. Stock priced...
By Yahoo! Finance | 3 weeks ago -
Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN)
On September 11, 2024, Myriad Genetics Inc's CEO, Paul Diaz, sold 15,000 shares at $26.72 per share, owning 977,378 shares now. The company focuses on molecular diagnostic tests for disease risk asses...
By Yahoo! Finance | 3 weeks ago -
Insider Sale: Director Heinrich Dreismann Sells Shares of Myriad Genetics Inc (MYGN)
Myriad Genetics Inc specializes in predictive medicine tests assessing disease risk for personalized treatment. Recent insider sells, including Heinrich Dreismann's 10,000 shares, point to a trend wit...
By Yahoo! Finance | 3 weeks ago
